In the Oncology VascHT29 Combo ELECT system, Keytruda (50,000 ng/mL) also reversed the hsa/mtCXCL8-mediated inhibition of key adhesion molecules like VCAM-1, CXCL-10, CXCL-9, and CD69 at the highest dose, promoting immune cell adhesion and recruitment into the tumor site. The gene discussed is CXCL9; the disease is neoplasm.